Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.95 | N/A | +32.62% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | -$0.95 | N/A | +32.62% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the quarter's performance, particularly regarding EPS. They emphasized their commitment to pipeline development.
We are pleased with our progress this quarter.
Our focus remains on advancing our pipeline.
Kodiak Sciences reported a narrower-than-expected loss per share, which contributed to a positive stock reaction, rising 6.67%. The lack of revenue details and guidance suggests uncertainty about future performance, but the EPS beat indicates some operational progress. Investors may view the EPS surprise as a sign of potential improvement in the company's financial health.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ROIVANT SCIENCES LTD
Nov 13, 2023